Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19356289 | 0.85 | NOTUM (0.49) | HDAC6NOTUMNPC1RAB9ADGAT1 | |
| SCHEMBL23140211 | 0.82 | NOTUM (0.46) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22116919 | 0.81 | NPC1 (0.56) | HDAC6NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL22116888 | 0.81 | NPC1 (0.59) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3756198 | 0.81 | NPC1 (0.64) | HDAC6NOTUMNPC1RAB9ADGAT1 | |
| SCHEMBL22116712 | 0.79 | NPC1 (0.57) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22116883 | 0.78 | NPC1 (0.60) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3228041 | 0.77 | DGAT1 (0.55) | HDAC6NPC1RAB9ADGAT1SMN1; SMN2 | |
| SCHEMBL22116917 | 0.77 | NPC1 (0.57) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19354612 | 0.77 | HDAC6 (0.49) | HDAC6NOTUMNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239892-A1 | COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF | ARKUDA THERAPEUTICS (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3724188-B1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2021-06-03 | — | — | US | disclosed |
| WO-2019118528-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163471-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN1 | HDAC6 706/4885NOTUM 3727/4885PTPN5 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.